BioSpace News Archive

Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with VBI Vaccines Inc. for the manufacture of their coronavirus vaccine candidates

AgilVax, Inc., a biopharmaceutical company that discovers and develops targeted antibody-based therapeutics to treat multiple types of cancer, announced today that the company has triggered Phase II funding worth $1.2 million from its Fast Track Small Business Innovation Research (SBIR) grant awarded by the National Cancer Institute (NCI).

SkyWater Technology, the trusted technology realization partner, announced the DARPA Three Dimensional Monolithic System-on-a-Chip (3DSoC) program, in collaboration with Massachusetts Institute of Technology (MIT), has entered its second phase

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today it has reached a significant milestone in its partnership with AstraZeneca, a global, science-led biopharmaceutical company aimed at reducing hospitalizations among patients with hyperkalemia, which is characterized by higher-than-normal potassium levels.

Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced an agreement with the Foundation for Angelman Syndrome Therapeutics (FAST) to collaborate in supporting preclinical studies of the potential benefit of Lixte’s proprietary lead clinical compound, LB-100, in a mouse model of Angelman Syndrome (AS)

As the search for COVID-19 therapies continues, convalescent plasma—distilled from the blood of people who have recovered from COVID-19—has emerged as a promising treatment option.

BioWave is further building its “Performance Team” and increasing the national awareness of the popular BioWaveGO through a partnership with U.S. Olympic Track Gold Medalist Tianna Bartoletta that will help amplify the GO’s unique pain relief pedigree and patented technology

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the results of a new review of clinical studies evaluating Caldolor® (ibuprofen) Injection, which was published in the journal Clinical Therapeutics.

IlluminOss Medical, a medical device company focused on minimally invasive orthopedic fracture repair, today announced that it has received expanded U.S. Food and Drug Administration (FDA 510k) clearance for its Photodynamic Bone Stabilization System for treatment of fractures of the fibula.

The World’s Leading Non-profit Organization in Prostate Cancer Research Encourages Americans to Eat Healthier While Raising Awareness About Health Disparities Among African American Men